4 withdrawn. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Withdrawn 4 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Urinary Bladder, Overactive: new trials by email Literature Review of Urinary Bladder, Overactive trials Research Report on Urinary Bladder, Overactive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2") 300 IU of BotuGelTM (60ml), 400 IU of BotuGelTM (60ml), TC-3 Gel - Overactive Bladder | Phase 1 / Phase 2 | Withdrawn | UroGen Pharma Ltd. | 2016-10-01 | 2017-06-16 | |
| Efficacy of Transcutaneous Nerve Stimulation on Improvement of Overactive Bladder Symptoms Sports TENS 2 - Overactive Bladder | Phase 2 | Withdrawn | Meir Medical Center | 2016-03-01 | 2016-03-16 | |
| Autologous Neo-Bladder Construct in Non-Neurogenic Overactive Bladder and Urge Predominant Incontinence Autologous neobladder construct - Overactive Bladder | Phase 2 | Withdrawn | Tengion | 2008-01-01 | 2018-06-08 | |
| Botulinum-A Toxin Injection for Detrusor Hyperreflexia in Spinal Cord Injury: A Non-Surgical Approach. Botox - Overactive Bladder, Urinary Incontinence | Phase 2 | Withdrawn | US Department of Veterans Affairs | 2015-06-26 |
Spinal Cord Injuries (1) · Urinary Incontinence (1)
Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Lower Urinary Tract Symptoms (4) · Male Urogenital Diseases (4) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Urinary Bladder Diseases (4) · Urogenital Diseases (4) · Urologic Diseases (4) · Urological Manifestations (4) · Central Nervous System Diseases (1) · Nervous System Diseases (1) · Spinal Cord Diseases (1) · Trauma, Nervous System (1) · Urination Disorders (1)
Meir Medical Center (1) · Tengion (1) · US Department of Veterans Affairs (1) · UroGen Pharma Ltd. (1)
Israel (2) · United States (2)
Angelo E Gousse, MD (1) · Ifat Klein, PhD (1) · Michael Tillinger, MD (1) · Michael Vainrib, M.D. (1)